Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ranjit Bindra
AddedMar 31, 2024
UpdatedMay 31, 2026
Ranjit Bindra

Ranjit Bindra

Co-Founder, Helix Therapeutics

CrunchbaseLinkedIn

Ranjit Bindra's Career

Helix Therapeutics
Helix Therapeutics

New Haven, CT, US

Co-Founder
Alphina Therapeutics
Alphina Therapeutics

Westport, CT, US

Founder
Cybrexa
Cybrexa

New Haven, CT, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ranjit Bindra's Career

Helix Therapeutics
Helix Therapeutics
$3.4M62006New Haven, CT, US
Co-Founder

Leadership at Helix Therapeutics

Kevin RakinKevin RakinBoard Member
Russell E TweeddaleRussell E TweeddaleBoard Member
Dr Peter M GlazerDr Peter M GlazerBoard Member
Joseph J CatinoJoseph J CatinoBoard Member
Peter M. GlazerPeter M. GlazerCo-Founder

Similar to Helix Therapeutics

Helix BioMedixHelix BioMedixBothell, WA, USDrug Developmentest. 1988Helix BioMedixBothell, WA, US · est. 1988

Helix BioMedix, Inc.: A US-based biopharmaceutical firm specializing in peptide discovery and rare skin disease treatment.

Public · $9.4M8
Helicon TherapeuticsHelicon TherapeuticsSan Diego, CA, USPharmaceuticalsest. 1997Helicon TherapeuticsSan Diego, CA, US · est. 1997

Helicon Therapeutics Inc.: Innovating cognitive disorder treatments through disruptive pharmaceuticals.

Series F · $108.8M13
HelixbindHelixbindMarlborough, MA, USDiagnostics, Microbiologyest. 2012HelixbindMarlborough, MA, US · est. 2012

US-based HelixBind, founded in 2012, operates in the biotechnology sector from Worcester, Massachusetts.

Seed · $22.7M27
HelexHelexNew York City, NY, USGene Editingest. 2021HelexNew York City, NY, US · est. 2021

NY-based Helex leverages genomics and intelligent data to create and distribute therapy-specific gRNAs.

Seed · $1.1M24
Alphina Therapeutics
Alphina Therapeutics
Series B$16.9M82020Westport, CT, US
Founder

Leadership at Alphina Therapeutics

Mark CockettMark CockettCEO

Similar to Alphina Therapeutics

Synnovation TherapeuticsSynnovation TherapeuticsWilmington, DE, USOncology Therapiesest. 2021Synnovation TherapeuticsWilmington, DE, US · est. 2021

Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.

Series A · $139M18
Nested TherapeuticsNested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50
Window TherapeuticsWindow TherapeuticsBoston, MA, USCancer Treatmentest. 2021Window TherapeuticsBoston, MA, US · est. 2021

Window Therapeutics: A biotech firm innovating targeted cancer treatments for unmet patient needs.

Angel · $256k4
Alterome TherapeuticsAlterome TherapeuticsSan Diego, CA, USOncology Therapeuticsest. 2021Alterome TherapeuticsSan Diego, CA, US · est. 2021

Alterome Therapeutics: Precision biotech developing targeted therapies for high-value oncogenic drivers.

Series A · $99M24
Cybrexa
Cybrexa
Series B$44.4M382017New Haven, CT, US
Co-Founder

Leadership at Cybrexa

Per HellsundPer HellsundCo-Founder & CEO
John HoustonJohn HoustonBoard Member

People Similar to Ranjit Bindra

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao